Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M238,404Revenue $M50,370Net Margin (%)18.7Altman Z-Score3.7
Enterprise Value $M239,343EPS $1.4Operating Margin %28.3Piotroski F-Score5
P/E(ttm)23.7Beneish M-Score-2.8Pre-tax Margin (%)25.1Higher ROA y-yN
Price/Book11.110-y EBITDA Growth Rate %4.7Quick Ratio1.0Cash flow > EarningsY
Price/Sales4.45-y EBITDA Growth Rate %3.8Current Ratio1.4Lower Leverage y-yN
Price/Free Cash Flow17.6y-y EBITDA Growth Rate %-14.0ROA % (ttm)14.0Higher Current Ratio y-yN
Dividend Yield %2.9PEG6.2ROE % (ttm)49.7Less Shares Outstanding y-yY
Payout Ratio %73.0Shares Outstanding M6,798ROIC % (ttm)37.6Gross Margin Increase y-yN

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2015-03-31 Reduce$32.1 - $36.505
($34.06)
$ 35.173%Reduce 1.24%2,788,126
RHHBYKen Fisher 2014-12-31 Add0.07%$34.16 - $37.92
($36.33)
$ 35.17-3%Add 49.26%2,823,025
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 35.17-4%Reduce 49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 35.1718%Add 99.00%3,606,140
RHHBYKen Fisher 2013-12-31 Reduce$31.96 - $35.24
($34.15)
$ 35.173%Reduce 0.26%1,812,112
RHHBYKen Fisher 2013-09-30 Add$30.655 - $33.765
($31.86)
$ 35.1710%Add 0.28%1,816,868
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.91)
$ 35.1714%Sold Out0
RHHBYKen Fisher 2013-06-30 Add$28.92 - $32.98
($30.91)
$ 35.1714%Add 0.90%1,811,804
RHHBYKen Fisher 2013-03-31 Add0.12%$25.615 - $29.3
($27.78)
$ 35.1727%Add 634.57%1,795,722
RHHBYKen Fisher 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 35.1743%Reduce 14.81%244,460
RHHBYTweedy Browne 2012-12-31 Reduce$23.08 - $25.68
($24.53)
$ 35.1743%Reduce 3.04%120,548
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.985 - $24.07
($22.5)
$ 35.1756%Reduce 24.31%124,328
RHHBYKen Fisher 2012-09-30 Reduce$20.985 - $24.07
($22.5)
$ 35.1756%Reduce 7.27%286,946
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.43 - $23.14
($21.18)
$ 35.1766%Add 543.36%8,547,954
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.43 - $23.14
($21.18)
$ 35.1766%Reduce 24.26%309,426
RHHBYKen Fisher 2012-03-31 Reduce-1.27%$20.885 - $22.5
($21.78)
$ 35.1761%Reduce 98.02%408,552
RHHBYTweedy Browne 2012-03-31 Reduce-0.04%$20.885 - $22.5
($21.78)
$ 35.1761%Reduce 22.19%164,260
RHHBYKen Fisher 2011-12-31 Reduce-0.26%$18.31 - $21.33
($20.11)
$ 35.1775%Reduce 15.75%20,679,972
RHHBYTweedy Browne 2011-12-31 Reduce$18.31 - $21.33
($20.11)
$ 35.1775%Reduce 0.53%211,110
RHHBYTweedy Browne 2011-09-30 Buy 0.1657%$18.66 - $22.625
($20.77)
$ 35.1769%New holding212,230
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about RHHBY:

    News about RHHBY:

    Articles On GuruFocus.com
    Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 
    Roche’s Oncology Drugs Drive Its Revenue Northwards In Q1 Apr 24 2015 
    Top Weighted Stocks in Tweedy Browne Global Value Fund's Portfolio Apr 22 2015 
    What Are The Intrinsic Factors Contributing To Pfizer’s Stock Movement? Mar 27 2015 
    AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
    Small Cap Biotech Growth Stocks For 2015 Mar 05 2015 
    Can These Three BioTech Companies Make It Big? Feb 20 2015 
    Pharmaceuticals Sector To See High Voltage Action in 2015 Jan 23 2015 
    Roche In Expansion Mode Jan 19 2015 
    Why Organovo is A Safe Buy? Dec 18 2014 

    More From Other Websites
    Exelixis-Roche's Skin Cancer Drug's FDA Review Delayed - Analyst Blog Jul 02 2015
    Is There Opportunity in Personalized Medicine? Jul 02 2015
    Evotec’s Partner Roche Provides Initial Update From Phase IIb Trial in Alzheimer’s Disease Jun 30 2015
    Roche 'High Efficacy' MS Drug Succeeds In Trials Jun 30 2015
    Roche's Multiple Sclerosis Studies Meet Primary Endpoint - Analyst Blog Jun 30 2015
    Genentech’s ocrelizumab Significantly Reduced Both Relapses and Disability Progression versus... Jun 30 2015
    Roche's Perjeta Recommended for Pre-Surgery Breast Cancer - Analyst Blog Jun 29 2015
    Clinical value of Roche's CINtec® PLUS Cytology test confirmed for women with abnormal cervical... Jun 16 2015
    Moody's: Immuno-oncology drugs credit positive for drug makers; competition high Jun 15 2015
    Ventana receives FDA approval for the first fully automated IHC companion diagnostic to identify... Jun 15 2015
    Ariosa receives CE mark for its FORTE Software to support Harmony™ Prenatal Test Jun 11 2015
    Ariosa grants licenses to laboratories to perform non-invasive prenatal testing (NIPT) based on... Jun 11 2015
    Ariosa receives CE mark for its FORTE Software to support Harmony™ Prenatal Test Jun 11 2015
    Ariosa grants licenses to laboratories to perform non-invasive prenatal testing (NIPT) based on... Jun 11 2015
    Roche's Actemra Gets Breakthrough Therapy Designation - Analyst Blog Jun 10 2015
    Prothena (PRTA) Starts Phase I Study on Psoriasis Candidate - Analyst Blog Jun 10 2015
    FDA Grants Breakthrough Therapy Designation for Actemra (tocilizumab) in Systemic Sclerosis Jun 10 2015
    Roche to Develop Diagnostic Test for Cardiovascular Disease - Analyst Blog Jun 09 2015
    Roche Takes Another Shot at Alzheimer's After Biogen Success Jun 09 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Steve.dunfield@google
    ReplySteve.dunfield@google - 1 year ago
    Adjust for split?
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK